Key Takeaways
- AstraZeneca shares plummeted up to 9% following disappointing results from Wainua’s late-stage heart disease study
- The drug failed to demonstrate a statistically significant reduction in cardiovascular deaths and heart complications in ATTR-CM patients during the 140-week study period
- A majority of participants (57%) were receiving stabilizer medications at enrollment, potentially obscuring Wainua’s therapeutic effects
- Financial analysts pointed to flawed trial methodology rather than drug inefficacy, though questioned management’s clinical development expertise
- Partner company Ionis Pharmaceuticals declined 13.8% in premarket activity; competitor Alnylam jumped 17%
Shares of AstraZeneca experienced their sharpest single-session decline since March 2020 on Thursday, falling as much as 9.1% in London markets after the pharmaceutical giant announced that Wainua, its experimental cardiac therapy, missed its primary endpoint in a pivotal late-stage clinical study.
In U.S. premarket trading, NYSE-listed AZN shares declined 8.4%, erasing approximately £23.3 billion ($31.21 billion) from the company’s total market capitalization at the session’s lowest point.
The investigational treatment was evaluated in 1,432 participants diagnosed with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), an uncommon cardiac disorder characterized by abnormal protein accumulation in heart tissue, which impairs the organ’s pumping capacity. Global prevalence estimates suggest between 300,000 and 500,000 individuals suffer from this condition.
According to Thursday morning’s press release from AstraZeneca, Wainua failed to demonstrate statistically meaningful improvements in cardiovascular mortality and recurrent cardiac events compared to placebo treatment over the 140-week observation period.
Questions Arise Over Study Methodology
The outcome surprised market analysts, with most not anticipating a primary endpoint failure given encouraging data from Amvuttra, a competing therapy developed by Alnylam Pharmaceuticals.
The issue appears rooted in the trial’s fundamental structure. At study initiation, 57% of enrolled patients were already receiving stabilizer medications, with an additional 24% commencing stabilizer therapy during the trial period. Because stabilizers operate through mechanisms distinct from Wainua—which functions as a gene silencing agent—the concurrent use of both treatment modalities complicated efforts to isolate and quantify Wainua’s incremental therapeutic contribution.
Among the patient subset not receiving stabilizer therapy at baseline, Wainua demonstrated a “nominally significant” clinical benefit. However, this subgroup finding proved insufficient to satisfy the study’s predetermined primary efficacy criterion.
Analysts at Jefferies noted that AstraZeneca “is meant to be able to have exceptionally good trial design ability,” suggesting the design-related failure could damage leadership credibility. The investment bank has revised its risk-adjusted revenue projections downward by $2.5 billion for the medication.
BofA analyst Sachin Jain characterized the outcome as “a surprise,” observing that market participants had dismissed the possibility of a trial miss given the existing positive competitor evidence.
Future Outlook for Wainua Development
Barclays analysts indicated they don’t anticipate AstraZeneca will finance a new monotherapy study for Wainua, reasoning that such an approach would be unlikely to secure regulatory authorization within the current decade and would trail substantially behind Alnylam’s already commercialized treatment.
Citi analysts suggested that pursuing supplemental regulatory approvals for Wainua in ATTR-CM now appears improbable, particularly given Amvuttra’s established market position for treating the condition.
Wainua’s current regulatory authorization remains valid. The medication has secured approval across more than 20 nations for treating polyneuropathy—a nerve disorder—and contributed $212 million in product sales for AstraZeneca during 2025.
Jefferies maintained that the trial setback doesn’t jeopardize AstraZeneca’s ambitious $80 billion annual revenue objective by 2030, which relies on launching up to 20 novel therapeutics. The analysts suggested the stock may remain under pressure until data emerges from the AVANZAR oncology study.
U.S.-traded development partner Ionis Pharmaceuticals dropped 13.8% in premarket sessions. Alnylam shares surged 17% while BridgeBio advanced between 11% and 16%.
AstraZeneca stated the findings “support greater scientific understanding of treatment approaches” for patients with ATTR-CM.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
